GoodRx Q2 Earnings Fall Short of Expectations with EPS at 4c
PorAinvest
viernes, 8 de agosto de 2025, 5:57 am ET1 min de lectura
GDRX--
The medication savings platform saw a 1% year-over-year (YoY) increase in revenue, driven by a 32% growth in pharma manufacturer solutions revenue to $35.0 million. However, prescription transactions revenue decreased by 3% to $143.1 million, primarily due to a 14% decline in Monthly Active Consumers, attributed to changes in the retail pharmacy landscape, including store closures and volume reduction in integrated savings programs [2].
CEO Wendy Barnes expressed excitement about the company's progress, highlighting new deals with pharmaceutical manufacturers and the launch of a condition-specific subscription product for erectile dysfunction. This new offering aims to reduce friction in the healthcare system and serve as a complement to insurance.
Despite the near-term challenges, GoodRx expects pharma manufacturer solutions to grow as a percentage of total revenue in the near to medium term. The company forecasts adjusted EBITDA between $265-$275 million for the full year 2025, representing 2-6% growth over 2024 [2].
GoodRx repurchased 10.2 million shares of Class A common stock for $46.4 million during the quarter, with $143.0 million remaining in its share repurchase program.
References:
[1] https://www.investing.com/news/earnings/goodrx-shares-tumble-as-q2-earnings-miss-expectations-93CH-4174853
[2] https://www.tradingview.com/news/tradingview:ae1287654b1a0:0-goodrx-holdings-inc-sec-10-q-report/
GoodRx reported Q2 EPS of 4c, missing consensus of 10c, and revenue of $203.1M, also below consensus of $205.71M. CEO Wendy Barnes expressed excitement about the company's progress, citing new deals with pharma and the launch of a condition subscription product for erectile dysfunction. The company aims to reduce friction in the healthcare system and serve as a complement to insurance.
GoodRx Holdings, Inc. (NASDAQ: GDRX) reported its second-quarter earnings on July 2, 2025, which fell short of analyst expectations. The company's earnings per share (EPS) of $0.04 missed the consensus estimate of $0.10, while revenue of $203.1 million was also below the expected $205.87 million [1].The medication savings platform saw a 1% year-over-year (YoY) increase in revenue, driven by a 32% growth in pharma manufacturer solutions revenue to $35.0 million. However, prescription transactions revenue decreased by 3% to $143.1 million, primarily due to a 14% decline in Monthly Active Consumers, attributed to changes in the retail pharmacy landscape, including store closures and volume reduction in integrated savings programs [2].
CEO Wendy Barnes expressed excitement about the company's progress, highlighting new deals with pharmaceutical manufacturers and the launch of a condition-specific subscription product for erectile dysfunction. This new offering aims to reduce friction in the healthcare system and serve as a complement to insurance.
Despite the near-term challenges, GoodRx expects pharma manufacturer solutions to grow as a percentage of total revenue in the near to medium term. The company forecasts adjusted EBITDA between $265-$275 million for the full year 2025, representing 2-6% growth over 2024 [2].
GoodRx repurchased 10.2 million shares of Class A common stock for $46.4 million during the quarter, with $143.0 million remaining in its share repurchase program.
References:
[1] https://www.investing.com/news/earnings/goodrx-shares-tumble-as-q2-earnings-miss-expectations-93CH-4174853
[2] https://www.tradingview.com/news/tradingview:ae1287654b1a0:0-goodrx-holdings-inc-sec-10-q-report/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios